Lymph node-targeted vaccine elicits COVID-19 protection in vivo
Posted: 23 September 2021 | Anna Begley (Drug Target Review) | No comments yet
Elicio Therapeutics’ lymph node-targeting vaccine displayed cellular and humoral immunity to SARS-CoV-2 in a pre-clinical study.


Elicio Therapeutics has announced positive pre-clinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit.
Elicio assessed the ability of ELI-005, containing AMP-CpG, to promote immunity directed against an admixed SARS-CoV-2 Spike receptor binding domain (RBD) protein in mice and non-human primates. Comparator vaccination with alum and unmodified CpG were included to assess immune response induction of a lymph node targeted adjuvant relative to either a depot forming or systemically distributed adjuvant.
The results suggest that efficient delivery of AMP-CpG to the lymph nodes enables cellular and humoral immunity and can be applied for rapid development of prophylactic or therapeutic vaccine candidates targeting a variety of disease specific antigens.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
According to the team, the Spike RBD sequence is an important target for the immune response as it is the target for neutralising antibody responses to SARS-CoV-2. These Spike antigens also contain T-cell epitopes that generate cell mediated immunity. The strong T-cell responses generated by ELI-005 indicate that it may enhance broad protection against these variants since most amino acid regions recognised by T cells have been conserved in variants of concern including the Beta (B.1.351) and Alpha (B.1.1.7) strains.
“We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens. This dual response is critical in developing broad protective immunity in patients,” commented Peter DeMuth, vice president of research at Elicio Therapeutics. “The cross-reactivity to variants of concern and induction of potent potentially cross-reactive T cells are crucial benefits as the virus continues to evolve. Although we are still in the early stages of studying this adjuvant, this data shows AMP-CpG has the potential to enhance a broad spectrum of vaccines beyond SARS-CoV-2.”
Data from the summit can be found here.
Related topics
Drug Targets, Immunology, In Vivo, Protein, T cells, Targets, Vaccine
Related conditions
Covid-19
Related organisations
Elicio Therapeutics
Related people
Peter DeMuth